➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Colorcon
Harvard Business School
Moodys
McKinsey

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,470,842


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,470,842 protect, and when does it expire?

Patent 8,470,842 protects VARUBI and is included in two NDAs.

This patent has twenty-nine patent family members in fifteen countries.

Summary for Patent: 8,470,842
Title:Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza- -spiro[4.5]decan-2-one and preparation process therefor
Abstract: Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
Inventor(s): Hu; Mengwei (Washington, NJ), Paliwal; Sunil (Monroe Township, NJ), Shih; Neng-Yang (Lexington, MA), Guenter; Frank Bruno (Schachen, CH), Mergelsberg; Ingrid (Mahwah, NJ)
Assignee: OPKO Health, Inc. (Miami, FL)
Application Number:12/614,108
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,470,842

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera VARUBI rolapitant hydrochloride EMULSION;INTRAVENOUS 208399-001 Oct 25, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY ⤷  Free Forever Trial
Tersera VARUBI rolapitant hydrochloride TABLET;ORAL 206500-001 Sep 1, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,470,842

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 060353 ⤷  Free Forever Trial
Canada 2648604 ⤷  Free Forever Trial
China 101437821 ⤷  Free Forever Trial
China 102276606 ⤷  Free Forever Trial
European Patent Office 2004646 ⤷  Free Forever Trial 300898 Netherlands ⤷  Free Forever Trial
European Patent Office 2004646 ⤷  Free Forever Trial PA2017031 Lithuania ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Harvard Business School
Merck
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.